Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent

Transfusion

Volumn 55, Issue 2, 2015, Pages 405-412

  McDowell, Kristy L ^a   Nag, Nabanita ^a   Franco, Zulmarie ^a   Bu, Ming ^a   Piccardo, Pedro ^a   Cervenak, Juraj ^a   Deslys, Jean Philippe ^b   Comoy, Emmanuel ^b   Asher, David M ^a   Gregori, Luisa ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD REFERENCE MATERIAL; BLOOD SAMPLING; BRAIN HOMOGENATE; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PLASMA; PROTEIN DETERMINATION; TERMINALLY ILL PATIENT; VARIANT CREUTZFELDT JAKOB DISEASE; VARIANT CREUTZFELDT JAKOB DISEASE AGENT; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; CREUTZFELDT JAKOB DISEASE; DISEASE MODEL; FEMALE; HUMAN; MOLECULAR GENETICS; PRION; STANDARD; TRANSMISSION;

PRION;

AMINO ACID SEQUENCE; ANIMALS; CREUTZFELDT-JAKOB SYNDROME; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MOLECULAR SEQUENCE DATA; PRIONS; REFERENCE STANDARDS;

EID: 84922961110     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12841     Document Type: Article

References (40)

1. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-925.
2. Brown P, Brandel JP, Sato T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 2012; 18: 901-907.
3. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-421.
4. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
5. UK HPA. Editorial team. New case of transfusion-associated vCJD in the United Kingdom. Euro Surveill 2006; 11:pii= 2895. [cited 2014 Aug 14]. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2895
6. UK HPA. Editorial team. Fourth case of transfusion-associated vCJD infection in the United Kingdom. Euro Surveill 2007; 12:pii= 3117. [cited 2014 Aug 14]. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3117
7. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-529.
8. Transfusion Medicine Epidemiology Review (TMER). [cited 2014 Apr 30]. Available from: http://www.cjd.ed.ac.uk/TMER/TMER.htm
9. Garske T, Ghani AC,. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PloS One 2010; 5: e15626.
10. Bennett P, Daraktchiev M,. Blood-borne transmission of vCJD re-examination of scenarios. 2011. [cited 2014 Apr 30]. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-129925
11. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. Br Med J 2013; 347: f5675.
12. CDC. vCJD cases reported in the US. June 3, 2014. [cited 2014 Jun 8]. Available from: http://www.cdc.gov/ncidod/dvrd/vcjd/factsheet-nvcjd.htm#reported
13. USDA. History of BSE in the United States. 2012. [cited 2014 Apr 30]. Available from: http://www.aphis.usda.gov/animal-health/animal-diseases/bse/history.shtml
14. FDA. Guidance for industry revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. May 2010. [cited 2014 Apr 30]. Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074100.htm
15. TSEAC. Draft quantitative risk assessment of vCJD risk potentially associated with the transfusion of red blood cells in the U.S. 2013. [cited 2014 Apr 30]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/TransmissibleSpongiformEncephalopathiesAdvisoryCommittee/UCM343264.pdf
16. Edgeworth JA, Farme M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011; 377: 487-493.
17. Orrú CD, Wilham JM, Raymond LD, et al. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBio 2011; 2: e00078-11.
18. Castilla J, Saá P, Soto C,. Detection of prions in blood. Nat Med 2005; 11: 982-985.
19. Rubenstein R, Chang B, Gray P, et al. A novel method for preclinical detection of PrPSc in blood. J Gen Virol 2010; 91: 1883-1892.
20. Cooper JK, Andrews N, Ladhani K, et al. Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease. Vox Sang 2013; 105: 196-204.
21. NIBSC. Evaluation of potential tests for vCJD for assess to rare samples-draft 1. [cited 2014 Apr 30]. Available from: http://www.nibsc.org/spotlight/cjd-resource-centre/cjd-tests.aspx
22. TSEAC. September 19, 2006. Topic II Potential screening assays to detect blood and plasma donors infected with agents of transmissible spongiform encephalopathies (TSE agents or prions): possible FDA review criteria and related issues. 2006. [cited 2014 Apr 30]. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4240b1-index.htm
23. Houston F, McCutcheon S, Goldmann W, et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008; 112: 4739-4745.
24. Nemecek J, Nag N, Carlson CM, et al. Red-backed vole brain promotes highly efficient in vitro amplification of abnormal prion protein from macaque and human brains infected with variant Creutzfeldt-Jakob disease agent. PloS One 2013; 8: e78710.
25. Minor P, Newham J, Jones N, et al.; WHO Working Group on International Reference Materials for the Diagnosis and Study of Transmissible Spongiform Encephalopathies. Standards for the assay of Creutzfeldt-Jakob disease specimens. J Gen Virol 2004; 85: 1777-1784.
26. Reed LJ, Muench H,. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497.
27. Piccardo P, Manson JC, King D, et al. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A 2007; 104: 4712-4717.
28. Herzog C, Salès N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 2004; 363: 422-428.
29. Herzog C, Rivière J, Lescoutra-Etchegaray N, et al. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol 2005; 79: 14339-14345.
30. Tattum MH, Jones S, Pal S, et al. Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification. Transfusion 2010; 50: 996-1002.
31. Thorne L, Terry LA,. In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie. J Gen Virol 2008; 89: 3177-3184.
32. Lacroux C, Vilette D, Fernández-Borges N, et al. Prionemia and leukocyte-platelet-associated infectivity in sheep transmissible spongiform encephalopathy models. J Virol 2012; 86: 2056-2066.
33. Elder AM, Henderson DM, Nalls AV, et al. In vitro detection of prionemia in TSE-infected cervids and hamsters. PloS One 2013; 8: e80203.
34. Lasmézas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. Nature 1996; 381: 743-744.
35. Lasmézas CI, Comoy E, Hawkins S, et al. Risk of oral infection with bovine spongiform encephalopathy agent in primates. Lancet 2005; 365: 781-783.
36. TSEAC. Comoy, E. Recent progress in developing a relevant animal model for vCJD agent in blood. 2009. Transcripts. 292-307. [cited 2014 Aug 14]. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/TransmissibleSpongiformEncephalopathiesAdvisoryCommittee/ucm129559.htm
37. Lescoutra N, Jaffre N, Culeux A, et al. Update on the ability of the prion capture filter, P-Capt™ to delay onset of an original myelopathic disease observed in primates exposed to prion infected blood products. Poster#P-383. Vox Sang 2013; 105 (s1): 197. ISBT Annual Meeting.
38. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
39. Ritchie DL, Boyle A, McConnell I, et al. Transmissions of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. J Gen Virol 2009; 90: 3075-3082.
40. Jackson GS, Burk-Rafel J, Edgeworth JA, et al. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. JAMA Neurol 2014; 71: 421-428.